FDA Warns of Higher-Than-Expected Long-Term Failure Risk With Hintermann H3 Ankle Replacement

If you (or a loved one) has a Hintermann Series H3 total ankle replacement, the U.S. Food and Drug Administration (FDA) updated its safety guidance on June 3, 2026. The update focuses on a higher-than-expected long-term risk of device failure, including the potential need for revision surgery and polyethylene (plastic) component fracture.

The key practical takeaway is that FDA does not recommend surgery to remove the implant if it’s working well and you have no new or worsening pain or symptoms. Instead, FDA urges continued follow-up and prompt contact with your health care provider if you develop specific red-flag changes.

What FDA updated on June 3, 2026

FDA says its updated recommendations are based on the “totality of data,” including mandated postmarket studies, scientific literature, and other real-world sources (such as registry and adverse-event reporting). FDA highlights:

Elevated long-term risk of device failure
Higher-than-expected risk of revision surgery
Risk of polyethylene fracture (plastic breakage)

FDA also says that, when possible, people considering the H3 TAR system should discuss other available treatment options with their health care provider.

FDA’s “contact your health care provider” symptoms (exact list)

If you already have the H3 TAR system and it is functioning well, FDA does not recommend surgery to remove it. But FDA says to contact your health care provider if you are experiencing any of the following:

Any new or worsening pain or swelling in your ankle
Inability to use your ankle or bear weight
Instability of your ankle
Grinding or other unusual noise from your implanted device
Weakness around your implanted device

FDA also notes that your health care provider may do a physical exam and get X-rays. In some instances, a CT scan may be needed to assess whether the plastic component is broken.

Safety warning vs. recall: what’s the difference?

It can be confusing when you see multiple FDA actions for the same product family. Here’s the practical distinction:

The June 3, 2026 safety communication warns about higher-than-expected long-term device failure risk, including revision surgery and polyethylene fracture.
The Class 2 recall posted June 10, 2026 is about incorrect packaging/labeling—FDA says the left implant packaging and labeling included a right implant device.

In other words: the recall issue is a packaging/labeling problem. The safety communication is about long-term failure risk and what to do if certain new symptoms develop. They are related to the overall product, but they are not the same message.

If you already have the H3 implant: what to do now

Keep your existing follow-up schedule if your H3 TAR system is functioning well and you have no new or worsening symptoms.
Don’t ignore changes: if you notice any FDA red-flag symptoms, contact your health care provider promptly.
Ask targeted questions at your next visit (or sooner if symptoms start). For example: “What imaging would you use if I develop pain, swelling, weakness, instability, or unusual noises?”
Bring your surgery paperwork so your clinician can document which implant you received (for example, the implant name/model from your operative records).
Report problems if you’ve had complications, since FDA encourages reporting to help identify safety concerns and improve patient safety.

If you end up needing additional surgery, costs and insurance coverage can vary by plan and location. You can ask the surgeon’s office about expected out-of-pocket costs ahead of time.

If you’re considering surgery: questions to bring to your pre-op visit

FDA says people considering the H3 TAR system should:

Discuss all available treatment options for a painful arthritic ankle.
Understand the benefits and risks of ankle fusion (arthrodesis) and other ankle replacement devices.
If your clinician recommends the H3 TAR system, ask why it’s the right choice for your situation compared with other options.

This matters for older adults because long-term planning for mobility, safety, and follow-up care can influence what “best option” means for your life over many years.

Watch for infection signs too (general guidance after joint replacement)

FDA’s red-flag list focuses on device-related symptoms. Separately, any joint replacement can develop an infection. The American Academy of Orthopaedic Surgeons (AAOS) lists possible infection symptoms after joint replacement, including:

Pain that does not change with activity
Fatigue
Redness and swelling at the incision site
Wound drainage (usually more than 10 days after surgery)
Possibly increased pain or stiffness in a previously well-functioning joint

AAOS also notes that fever is no longer considered a sign of infection after joint replacement.

CDC guidance for surgical site infections advises: if you have symptoms of infection—such as redness and pain at the surgery site, drainage, or fever—call your health care provider immediately.

For caregivers: a simple tracking plan

Track changes: write down when symptoms started, whether they’re getting worse, and what you observe (noise, swelling, trouble bearing weight).
Bring notes to appointments so the clinician can connect the history to the exam and any imaging.
Help coordinate care: if the clinician orders X-rays or CT, assist with scheduling and transportation.

When to seek professional help

Contact your health care provider promptly if you have any of FDA’s H3 red-flag symptoms: new/worsening pain or swelling, inability to use/bear weight, ankle instability, grinding/unusual noise, or weakness around the implant.
Call immediately if you develop possible infection symptoms (especially redness/pain at the surgical site, drainage, or fever) as CDC describes for surgical site infections.
Seek emergency care if symptoms are severe or your loved one appears dangerously ill. AAOS notes that infection symptoms can range up to life-threatening septic shock.

FDA’s message is clear but also reassuring: if your H3 total ankle replacement is working well, FDA does not recommend routine removal. The safest next step is to stay on follow-up—and act quickly if new or worsening symptoms appear.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.